If not, please take a few moments to fill out the form below. It’s free, and ensures that you receive regular alerts to the latest clinical news and other content.

Keep me logged in Forgot your password?

Please wait...

Please wait...

 Dyslipidemia

NDA Filed for Mixed Dyslipidemia Treatment

August 19, 2009

Abbott (Abbott Park, Ill.) and AstraZeneca (London, UK) have submitted a New Drug Application (NDA) for an investigational drug to treat mixed dyslipidemia. Pending approval of the NDA, the drug will be marketed as Certriad.
 
Popular Topics
Acute Kidney Injury AKI Androgen Deprivation Anemia Benign Prostatic Hyperplasia Bladder Cancer BPH Cardiovascular Disease Chronic Kidney Disease Circumcision CKD CVD Dialysis End-stage Renal Disease Hemodialysis Hyperphosphatemia Kidney Cancer Overactive Bladder Prostate Cancer Renal Cell Carcinoma Reproductive Medicine Secondary Hyperparathyroidism Transplantation Urinary Incontinence Urology

 

© 2012 Haymarket Media, Inc.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions